

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity :</b> CurveBeam AI Limited
<b>ABN</b> : 32 140 706 618

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Waradana Malitha Hashan De Silva
<b>Date of last notice</b>	4 <sup>th</sup> November 2024

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Through HDS SMSF Pty Ltd (HDS SMSF A/C), Mr De Silva is a beneficiary
<b>Date of change</b>	28 <sup>th</sup> November 2024

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p><b>Direct</b>  565,493 ordinary shares</p> <p>124,007 Noteholder Options, with an exercise price of \$0.6720 and an expiry date of 21 August 2025</p> <p>2,058,824 Plan Options, with an exercise price of \$0.543 and expiry date of 11 May 2029</p> <p>46,875 Plan Options, with a zero exercise price, expiry date of 16 August 2029</p> <p>109,375 Plan Options with a zero exercise price, expiry date of 13<sup>th</sup> February 2030</p> <p><b>Indirect</b>  320,928 ordinary shares, for HDS SMSF Pty Ltd (HDS SMSF A/C) Mr De Silva is a beneficiary</p> <p>11,111,111 ordinary shares, held by KP Rx Healthcare Opportunities Fund, Mr De Silva is a Founder and Managing Partner</p>
<p><b>Class</b></p>	<p>Ordinary Shares</p>
<p><b>Number acquired</b></p>	<p>26,454</p>
<p><b>Number disposed</b></p>	<p>-</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$2,936.47 (a range of 11c to 12c per share)</p>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p><b>Direct</b></p> <p>565,493 ordinary shares</p> <p>124,007 Noteholder Options, with an exercise price of \$0.6720 and an expiry date of 21 August 2025</p> <p>2,058,824 Plan Options, with an exercise price of \$0.543 and expiry date of 11 May 2029</p> <p>46,875 Plan Options, with a zero exercise price, expiry date of 16 August 2029</p> <p>109,375 Plan Options with a zero exercise price, expiry date of 13<sup>th</sup> February 2030</p> <p><b>Indirect</b></p> <p>347,382 ordinary shares, for HDS SMSF Pty Ltd (HDS SMSF A/C), Mr De Silva is a beneficiary</p> <p>11,111,111 ordinary shares, held by KP Rx Healthcare Opportunities Fund, Mr De Silva is a Founder and Managing Partner</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	27 <sup>th</sup> November 2024

---

<sup>+</sup> See chapter 19 for defined terms.